FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4289778739> ?p ?o ?g. }

• W4289778739 endingPage "2842" @default.
• W4289778739 startingPage "2842" @default.
• W4289778739 abstract "Postoperative endophthalmitis has always been a nightmare for the patients and surgeons alike. Around 90% of patients having post trabeculectomy endophthalmitis and 40% of patients having postcataract surgery endophthalmitis would end up having final visual acuity worse than 20/200.[1] The economic burden of endophthalmitis is also significant as stated by Schmier et al.;[2] the average adjusted ophthalmic reimbursements were 156% greater for cases that developed endophthalmitis than for subjects having uncomplicated cataract surgery. The psychological impact on quality of life is also significant leading to poorer psychological well-being and ability to maintain a role in daily life.[3] Even after decades of publishing, the endophthalmitis vitrectomy study (EVS)[4] still holds key role in the endophthalmitis management algorithms. Ho et al.[5] in their study suggested that early vitrectomy may be beneficial for all cases and not just the ones with light perception or worse visual acuity as stated in EVS.[4] Few other studies also favor early vitrectomy.[67] The notable fact that EVS includes only postcataract surgery cases makes its significance diluted in cases post procedures other than cataract surgery specially in current era of variety of intravitreal injections, newer and more advanced surgical techniques, and newer drugs. Additionally, the postcataract endophthalmitis was proven to have better visual outcome than post trabeculectomy, postintravitreal injection, and endogenous endophthalmitis.[5] In treating endophthalmitis, antibiotics are the mainstay. Their augmentation with steroids remains controversial as ever. Many studies have reported that steroids do not add additional benefit to the final visual acuity of the patients.[8] The time of starting of steroids remains in the uncertainty. Concerns have been expressed regarding their safety and long-term outcomes. Shah et al.[9] reported worse visual outcome with the use of intravitreal steroids. In contrary to these reports, multiple studies have reported favorable outcomes with the use of intravitreal steroids and some reported that with the use of steroids even though the visual acuity did not have benefit, the intraocular inflammation and the overall morbidity related to the condition were helped.[101112] Albrecht et al.[11] in their study analyzed groups of “postcataract surgery,” “bleb related,” and “other” endophthalmitis, and they found a clinical trend of better visual acuity in the subgroup of postcataract surgery endophthalmitis patients who received steroids. Gan et al.[12] found out in their prospective placebo-controlled study that there was a trend toward better visual outcome in patients with suspected bacterial endophthalmitis when treatment with intravitreal antibiotics was combined with intravitreal dexamethasone. Multiple animal studies have also found out intraocular steroids to be beneficial in endophthalmitis.[81314] The authors in their practice have also noticed that during vitrectomy, immediate KOH mount assessment in a standard lab to rule out fungal infection and adjuvant intravitreal dexamethasone has helped their patients with faster recovery and less inflammation. The current metaanalysis does not show any clear visual benefit from use of adjuvant intravitreal dexamethasone in bacterial endophthalmitis.[15] Prospective randomized controlled trials for the treatment of postprocedure endophthalmitis with multicenter involvement are needed to clarify the gray areas around the usage of steroids and formulating preferred practice patterns for the new era." @default.
• W4289778739 created "2022-08-04" @default.
• W4289778739 creator A5006561493 @default.
• W4289778739 creator A5015782848 @default.
• W4289778739 creator A5030468814 @default.
• W4289778739 creator A5045658333 @default.
• W4289778739 date "2022-01-01" @default.
• W4289778739 modified "2023-09-30" @default.
• W4289778739 title "Commentary: Dexamethasone and dilemma" @default.
• W4289778739 cites W1966045299 @default.
• W4289778739 cites W2053845496 @default.
• W4289778739 cites W2059786811 @default.
• W4289778739 cites W2075806846 @default.
• W4289778739 cites W2078279139 @default.
• W4289778739 cites W2088811750 @default.
• W4289778739 cites W2111618627 @default.
• W4289778739 cites W2112797449 @default.
• W4289778739 cites W2541533720 @default.
• W4289778739 cites W2772077418 @default.
• W4289778739 cites W2775471501 @default.
• W4289778739 cites W2991671499 @default.
• W4289778739 cites W3023810821 @default.
• W4289778739 cites W4289778625 @default.
• W4289778739 cites W4299861055 @default.
• W4289778739 doi "https://doi.org/10.4103/ijo.ijo_3213_21" @default.
• W4289778739 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35918925" @default.
• W4289778739 hasPublicationYear "2022" @default.
• W4289778739 type Work @default.
• W4289778739 citedByCount "0" @default.
• W4289778739 crossrefType "journal-article" @default.
• W4289778739 hasAuthorship W4289778739A5006561493 @default.
• W4289778739 hasAuthorship W4289778739A5015782848 @default.
• W4289778739 hasAuthorship W4289778739A5030468814 @default.
• W4289778739 hasAuthorship W4289778739A5045658333 @default.
• W4289778739 hasBestOaLocation W42897787391 @default.
• W4289778739 hasConcept C118487528 @default.
• W4289778739 hasConcept C141071460 @default.
• W4289778739 hasConcept C2775888743 @default.
• W4289778739 hasConcept C2777235844 @default.
• W4289778739 hasConcept C2777824320 @default.
• W4289778739 hasConcept C2778257484 @default.
• W4289778739 hasConcept C2778527774 @default.
• W4289778739 hasConcept C2781242345 @default.
• W4289778739 hasConcept C71924100 @default.
• W4289778739 hasConceptScore W4289778739C118487528 @default.
• W4289778739 hasConceptScore W4289778739C141071460 @default.
• W4289778739 hasConceptScore W4289778739C2775888743 @default.
• W4289778739 hasConceptScore W4289778739C2777235844 @default.
• W4289778739 hasConceptScore W4289778739C2777824320 @default.
• W4289778739 hasConceptScore W4289778739C2778257484 @default.
• W4289778739 hasConceptScore W4289778739C2778527774 @default.
• W4289778739 hasConceptScore W4289778739C2781242345 @default.
• W4289778739 hasConceptScore W4289778739C71924100 @default.
• W4289778739 hasIssue "8" @default.
• W4289778739 hasLocation W42897787391 @default.
• W4289778739 hasLocation W42897787392 @default.
• W4289778739 hasLocation W42897787393 @default.
• W4289778739 hasLocation W42897787394 @default.
• W4289778739 hasOpenAccess W4289778739 @default.
• W4289778739 hasPrimaryLocation W42897787391 @default.
• W4289778739 hasRelatedWork W2046789353 @default.
• W4289778739 hasRelatedWork W2408335309 @default.
• W4289778739 hasRelatedWork W2409955530 @default.
• W4289778739 hasRelatedWork W2505001290 @default.
• W4289778739 hasRelatedWork W2618677365 @default.
• W4289778739 hasRelatedWork W3041812434 @default.
• W4289778739 hasRelatedWork W3199509315 @default.
• W4289778739 hasRelatedWork W4285259705 @default.
• W4289778739 hasRelatedWork W4289778739 @default.
• W4289778739 hasRelatedWork W4377094611 @default.
• W4289778739 hasVolume "70" @default.
• W4289778739 isParatext "false" @default.
• W4289778739 isRetracted "false" @default.
• W4289778739 workType "article" @default.